Navigation Links
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Date:1/11/2010

ld senior clinical positions at XOMA, including vice president of clinical science. In addition to overseeing clinical development programs at XOMA, Dr. Garovoy was responsible for managing clinical collaborations with external partners.

"Bavituximab is a promising new approach with broad potential for the treatment of solid cancers and other diseases," said Dr. Garovoy. "Based on the encouraging results seen in early clinical trials, I welcome the opportunity to collaborate with clinical researchers to establish the investigator-sponsored studies that will enhance our understanding of the clinical potential of this exciting new agent."

Dr. Garovoy has authored over 200 medical publications and holds two patents. He held teaching positions as a faculty member at Harvard Medical School and more recently as a Professor of Surgery and Medicine at the University of California, San Francisco. Dr. Garovoy received a BA degree from New York University and an MD degree with honors from the State University of New York Downstate Medical Center. He completed a post-graduate fellowship in Immunology and Transplantation at Harvard Medical School.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
2. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
3. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
8. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
9. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
10. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
11. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 24, 2014 According to new ... Data Center Types (Colocation, Enterprise, Telecom), by Design ... 1, Tier 2, Tier 3, Tier 4) - ... and segments the Data Center Construction Market into ... of revenues. This research report also identifies the ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... more convenient security to residences and private offices with their state-of-the-art ... businesses, hospitals, schools and the military is now accessible to the ... ... same innovative biometric technology used to enhance Hollywood films like Mission ...
... 27 MichBio, the association for,Michigan,s biosciences industry, ... to its program on day one of its ... Rock Financial ShowPlace Novi, MI. The,event will provide ... bioscience technologies and emerging companies to an audience ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today the company,s,participation and ... investor conferences in September., Conference: NewsMakers ... Millennium Broadway Hotel & Conference Center ... West 44th Street, New York Presentation Date: Thursday, September ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 3
(Date:10/29/2014)... EAST LANSING, Mich. – As bodies decompose, their ... Deciphering the clues they provide could mean the ... murder. , Michigan State University is using a ... to help Detroit death-scene investigators examine these changing ... such as geographical location of death, gender, race, ...
(Date:10/29/2014)... Virtually all organisms in the living world compete ... differ strongly in how much they invest into ... and eager to get access to high-quality resources, ... prudent use of the lower-quality resources that are ... competitiveness in animal and human societies seems to ...
(Date:10/28/2014)... news release is available in German . ... close relatives, the chimpanzees, acquire sufficient food when times ... National Park in Côte d,Ivoire researchers of the Max ... a clear example of how great apes can acquire ... show that chimpanzees make their sleeping nests more en ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3
... 2007Professor Gilles Gauthier of Universit Lavals Centre dtudes nordiques ... up the ArticWOLVES project as part of International Polar ... the research project aims to better understand the impact ... polar ecosystems. Dating back to the 1960s, Centre ...
... 24, 2007) New research published in the October ... Surgeons suggests that pregnant women suspected of having appendicitis ... the appendix) that can result in early delivery or ... the need to require more accurate diagnosis to avoid ...
... The vast majority of patients who had ... did not need mitral valve surgery three years ... improved function of the left ventricle (commonly known ... week at the Cardiovascular Research Foundations (CRF) nineteenth ...
Cached Biology News:$2.8 million for research into the impact of climate change on tundra wildlife 2Pregnant women at risk for unnecessary operations due to misdiagnosis of appendicitis 2New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3
...
... formation of phosphodiester bonds in the presence ... hydroxyl and 5' phosphate termini. The unique ... can be performed in 5 minutes (1). ... this enzyme. A T4 DNA Ligase ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: